Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Diagnostics and Stanbio Jointly Exhibit Expanded IVD Portfolio for First Time at AACC

Published: Tuesday, June 19, 2012
Last Updated: Tuesday, June 19, 2012
Bookmark and Share
Booth 1631, 17-19th July, L.A. Convention Centre, California.

Two leading global IVD businesses will be sharing the stage for the first time at the American Association for Clinical Chemistry’s Annual Meeting and Clinical Lab Expo (AACC 2012).

EKF Diagnostics, and AACC regulars Stanbio Laboratory (Boerne, Texas), will be exhibiting the EKF Diagnostics Group’s range of IVD products, which has expanded since Stanbio became part of EKF Diagnostics in June 2011.

At booth 1631, EKF Diagnostics will be premiering to the US market the Quo-Test and Quo-Lab glycated haemoglobin (HbA1c) analyzers for near-patient measurement and monitoring of diabetes.

Quo-Test, EKF Diagnostics’s flagship analyzer, is accurate, simple to use and delivers results in less than four minutes, making it ideal for the physician’s office. These industry-leading qualities have ensured that more than 1,000 units are already in use globally.

Quo-Lab is specifically designed for developing markets, and uses the same methodology as Quo-Test within an even more compact casing. The four-step testing procedure makes it a very cost effective option for small laboratories and diabetes clinics.

Stanbio Laboratory will focus on the Stanbio Beta-Hydroxybutyrate LiquiColor® (β-HB) Reagent System, which measures the main ketone produced during ketosis.

As it provides quantitative results, unlike traditional testing methods, β-HB is changing the way hospitals manage patients displaying symptoms of diabetic ketoacidosis. The liquid-stable reagent can be used on open channel analyzers from almost twenty different manufacturers.

To highlight the use of the Beta-Hydroxybutyrate LiquiColor® Reagent System, Stanbio Laboratory and EKF Diagnostics are hosting a symposium entitled, “The value, efficacy and efficiency of Beta-Hydroxybutyrate”.

This will be presented by renowned point-of-care expert, Dr James Nichols, Professor of Pathology at Tufts University School of Medicine, Boston, and Medical Director of Clinical Chemistry for Baystate Health in Springfield, Massachusetts.

Dr Nichols will discuss the relative merits of the various methods of testing for diabetic ketoacidosis, including β-HB.

The free symposium will take place at 11.30 am on Wednesday July 18th at the Westin Bonaventure Hotel, Los Angeles (15 minutes’ walk from the LA Convention Centre).

According to Julian Baines, Group CEO, “AACC Clinical Lab Expo is the first time we have showcased the full range of in vitro diagnostic products within the EKF Diagnostics portfolio. Our experts will be on hand to show delegates how our innovative and high-quality products in clinical chemistry and near-patient testing are improving patient outcomes by providing practitioners with fast and accurate results, which in turn allow them to make critical decisions.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!